Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab With P-GemOx for Newly Diagnosed Advanced ENKTL
NCT04127227Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2019
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), sponsored by Sun Yat-sen University. Started Oct 2019; status: active, not recruiting.
02
Drugs
sintilimab
03
Conditions
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
Beyond the preview
Go deeper on NCT04127227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04127227.